Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)

NCT00480194 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2012-05-07

No results posted yet for this study

Summary

The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting.

Conditions

  • Common Cold

Interventions

DRUG

xylometazoline hydrochloride and ipratropium bromide (ZyComb)

Common cold in a real-life OTC setting

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Nycomed Clinical Trial Operations · Headquaters

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-01-31
Completion
2008-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00480194 on ClinicalTrials.gov